Literature DB >> 9705265

Altered tropism of an ovine adenovirus carrying the fiber protein cell binding domain of human adenovirus type 5.

Z Z Xu1, G W Both.   

Abstract

Ovine adenovirus OAV287 (OAV) is phylogenetically and serotypically distinct from human Ad5. OAV grows productively in CSL503 foetal ovine lung cells and abortively infects several human cell lines. OAV has a unique fiber and a penton protein that lacks a recognisable integrin-binding motif. It is not known whether a secondary receptor is required for infection. A hybrid virus was constructed in which the cell binding domain on the OAV fiber protein was exchanged for the equivalent region from human adenovirus type 5. The hybrid OAV grew to titres that were 1 to 2 log10 lower than wild-type OAV in permissive ovine cells. Human Ad5 also infected CSL503 cells but failed to compete with OAV for receptor binding sites on those cells. However, the hybrid virus did compete with Ad5, consistent with its use of the Ad primary receptor. The hybrid virus was also neutralised by Ad5 antiserum whereas OAV was not. Human 293 kidney and LNCaP prostate cell lines that were not detectably infected by OAV were infected by the hybrid virus and other human prostate and breast cancer cell lines showed greatly enhanced infectivity. Thus, modification of the fiber cell binding domain was sufficient to profoundly alter the tropism of OAV, suggesting that the interaction between the primary receptor and the virus particle is the major factor controlling virus entry during infection. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9705265     DOI: 10.1006/viro.1998.9261

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  10 in total

1.  Ovine adenovirus vectors overcome preexisting humoral immunity against human adenoviruses in vivo.

Authors:  C Hofmann; P Löser; G Cichon; W Arnold; G W Both; M Strauss
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

2.  Dependence of adenovirus infectivity on length of the fiber shaft domain.

Authors:  D M Shayakhmetov; A Lieber
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

3.  Cryoelectron microscopy map of Atadenovirus reveals cross-genus structural differences from human adenovirus.

Authors:  Radosav S Pantelic; Linda J Lockett; Rosalba Rothnagel; Ben Hankamer; Gerald W Both
Journal:  J Virol       Date:  2008-05-28       Impact factor: 5.103

4.  Replication-defective bovine adenovirus type 3 as an expression vector.

Authors:  P S Reddy; N Idamakanti; Y Chen; T Whale; L A Babiuk; M Mehtali; S K Tikoo
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

5.  Usage of integrin and heparan sulfate as receptors for mouse adenovirus type 1.

Authors:  Sharmila Raman; Tien-Huei Hsu; Shanna L Ashley; Katherine R Spindler
Journal:  J Virol       Date:  2009-01-28       Impact factor: 5.103

Review 6.  Circumventing antivector immunity: potential use of nonhuman adenoviral vectors.

Authors:  Estrella Lopez-Gordo; Iva I Podgorski; Nicholas Downes; Ramon Alemany
Journal:  Hum Gene Ther       Date:  2014-03-25       Impact factor: 5.695

7.  Biology of ovine adenovirus infection of nonpermissive cells.

Authors:  Daniel Kümin; Christian Hofmann; Michael Rudolph; Gerald W Both; Peter Löser
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

8.  Construction, rescue, and characterization of vectors derived from ovine atadenovirus.

Authors:  Peter Löser; Christian Hofmann; Gerald W Both; Wolfgang Uckert; Moritz Hillgenberg
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

Review 9.  Development of nonhuman adenoviruses as vaccine vectors.

Authors:  Dinesh S Bangari; Suresh K Mittal
Journal:  Vaccine       Date:  2005-09-23       Impact factor: 3.641

Review 10.  Nonhuman Adenoviral Vector-Based Platforms and Their Utility in Designing Next Generation of Vaccines for Infectious Diseases.

Authors:  Marwa Alhashimi; Ahmed Elkashif; Ekramy E Sayedahmed; Suresh K Mittal
Journal:  Viruses       Date:  2021-07-29       Impact factor: 5.048

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.